Incendia Therapeutics Enrolls First Patient in Phase 1c Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor

On September 10, 2024 Incendia Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), reported that the first patient has been enrolled in the Phase 1c study of PRTH-101 for the treatment of patients with advanced or metastatic solid tumors (Press release, Incendia Therapeutics, SEP 10, 2024, View Source [SID1234646496]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In our Phase 1a and 1b studies, we were able to select an optimal dose and identify potential biomarkers to carry forward" said Irena Webster, SVP Development and Operations of Incendia. "The data from this study will inform the design of the Phase 2/3 program, for which planning and global feasibility are currently underway."

Dr. Joseph Paul Eder, CMO, added "Incendia, with its outstanding team of investigators and investigative sites, has determined a recommended Phase 2 dose of PRTH 101. PRTH 101 has shown consistent safety as a single agent and in combination with pembrolizumab. We will now focus on tumor types that have demonstrated signs of clinical activity and patient benefits."

The Phase 1c study will evaluate the safety, tolerability and anti-tumor activity of PRTH-101 as both a monotherapy and in combination with KEYTRUDA (pembrolizumab).

About PRTH-101
PRTH-101 is a therapeutic antibody that targets DDR1, a collagen binding protein and kinase present on epithelial cells. Some tumor cells are believed to co-opt DDR1 – collagen binding to build an impenetrable barrier around the tumor. By allosterically disabling DDR1, PRTH-101 disrupts tumor associated collagen alignment to permit immune cell access into the tumor core. In preclinical experiments, PRTH-101 mediated DDR1 blockade has demonstrated both single agent anti-tumor activity as well as marked augmentation of checkpoint inhibitor function. Tumor types that express high levels of DDR1-associated collagen barriers include thymic, colorectal, pancreatic, ovarian, glioma, and non-small cell lung cancer. Currently, there are no approved drugs that target DDR1.

About the Phase 1 Trial
The Phase 1 trial (NCT05753722) is a multi-center, open-label, dose escalation and dose expansion study that is expected to enroll up to 270 patients in the US with advanced or metastatic solid tumors. The goals of the study are to assess safety and tolerability of PRTH-101, evaluate anti-tumor activity in select indications alone and in combination with anti-PD-1 inhibitors, and determine dosing regimens for the Phase 2 clinical program. In addition to examining the clinical profile of PRTH-101, the trial will evaluate DDR1 and pathway-related proteins as predictive biomarkers for patients whose tumors respond to treatment.

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

On September 10, 2024 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, reported that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00 AM ET in New York, New York (Press release, Aclaris Therapeutics, SEP 10, 2024, View Source [SID1234646465]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

OncoHost Accepted to Present Poster Demonstrating PROphet®’s Application in Renal Cell Carcinoma at ESMO 2024

On September 10, 2024 OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, reported its selection to present a poster at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2024, which will take place from September 13 to 17, 2024, in Barcelona, Spain (Press release, OncoHost, SEP 10, 2024, View Source [SID1234646481]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, titled "A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma," highlights the extended application of OncoHost’s PROphet platform beyond non-small cell lung cancer (NSCLC) to renal cell carcinoma (RCC). This research represents a collaboration between OncoHost and Dana-Farber Cancer Institute, a world leader in adult and pediatric cancer treatment and research. The findings will be presented by Dr. Eddy Saad, MD, MSc, a Postdoctoral Research Fellow at Dana-Farber.

"In this work, we demonstrated that OncoHost’s plasma-based proteomic model, initially trained and validated in NSCLC, can also be applied to another tumor type, RCC, to risk stratify patients," said Dr. Eddy Saad, MD, MSc, Postdoctoral Research Fellow at Dana-Farber, and co-author of the abstract. "Moving forward, we aim to further develop and train an RCC-specific model and assess its predictive abilities to guide patient treatment."

The study explored the use of OncoHost’s PROphet platform in a cohort of 201 RCC patients treated with various therapies, including VEGFR tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or a combination of both. The results demonstrated that patients identified as PROphet-POSITIVE had significantly improved overall survival (OS) and progression-free survival (PFS) compared to PROphet-NEGATIVE patients, indicating the platform’s potential to predict clinical outcomes across various cancer types.

Furthermore, the research uncovered distinct subsets of circulating proteins associated with clinical benefit among patients treated with different therapies, suggesting that the proteomic features leveraged by the PROphet platform may have broad predictive value. These findings provide a strong foundation for further exploration of PROphet’s application in other cancer indications and treatment contexts.

"This research marks another important milestone for OncoHost, as it demonstrates the versatility and potential of our PROphet platform across different cancer types. By validating the use of our proteomic model in renal cell carcinoma, we are moving closer to our goal of providing personalized treatment plans that significantly improve patient outcomes," said Ofer Sharon, MD, CEO of OncoHost. "We are honored to partner with Dana-Farber in presenting these findings at ESMO (Free ESMO Whitepaper) 2024 and look forward to further expanding the clinical applications of our technology."

Poster Presentation Details
Title: A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presentation #: 1707P
Title: A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers.
Presenter: Eddy Saad, MD, MSc, Postdoctoral Research Fellow at Dana-Farber Cancer Institute
Date: Sunday, 15 September 2024

Xcell Biosciences Advances Labcorp Collaboration with Novel Platform for Automated Cell and Gene Therapy Manufacturing

On September 10, 2024 Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, reported it has advanced its collaboration with Labcorp with the installation of a new AVATAR Foundry system at the healthcare company’s Ann Arbor, Michigan site (Press release, Xcell Biosciences, SEP 10, 2024, View Source [SID1234646497]). This installation, part of the beta access program for Xcellbio’s latest instrument, allows scientists at Labcorp to extend the potency benefits observed in small-scale workflows on the previously installed AVATAR Odyssey platform up to large-scale automated cell therapy manufacturing workflows.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Xcellbio has developed the AVATAR incubator system for cell and gene therapy research and development with the AVATAR Odyssey system designed for small-scale research and process development needs. Its latest platform, the AVATAR Foundry system, is a current good manufacturing platform (cGMP) that delivers novel capabilities for improving the potency of cell and gene therapies. These capabilities are especially important for cell therapies targeting solid tumors, which often face overwhelming challenges in the hostile tumor microenvironment (TME).

"After using the AVATAR Odyssey system for more than two years, we have seen results demonstrating benefits for both cell therapy expansion rates and anti-tumor potency. We are eager to scale our workflows with the new AVATAR Foundry instrument, which could allow us to support customers early in their development of novel manufacturing techniques for cell and gene therapies," said Maryland Franklin, Ph.D., vice president and enterprise head of cell and gene therapy at Labcorp. "This technology complements our strong capabilities in analytical testing and our commitment to using potency assays and downstream analytics for monitoring and release of candidate therapies to provide delivery of only the most effective and reliable products."

Labcorp scientists have used AVATAR incubation technology to study the effectiveness and performance of cell therapy candidates grown in standard culture conditions versus those grown in customized levels of oxygen and pressure. The use of these custom conditions during cell expansion metabolically rewires therapeutic cells to improve their survival and persistent tumor killing activity in the harsh TME. Labcorp scientists have been going beyond in vitro studies with ongoing in vivo experiments to further evaluate this approach.

"Labcorp has long been one of Xcellbio’s closest collaborators, and we are pleased to include them as early members of our beta access program for the AVATAR Foundry," said Brian Feth, co-founder and CEO at Xcellbio. "We look forward to seeing the innovative ways they will use this platform to enhance their already impressive cell and gene therapy work."

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine

On September 10, 2024 BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, reported Dublin-3 final phase 3 efficacy data of its late clinical-stage agent Plinabulin in combination with docetaxel in second/third line (2L/3L) advanced and metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) wild-type (Press release, BeyondSpring Pharmaceuticals, SEP 10, 2024, View Source;utm_medium=rss&utm_campaign=beyondspring-delivers-oral-presentation-at-islac-2024-world-conference-on-lung-cancer-of-its-lead-anti-cancer-asset-plinabulin-showcasing-positive-final-phase-3-data-in-2l-3l-nsclc-egfr-wild-type-with [SID1234646466]). The lead principal investigator, Dr. Trevor Feinstein from Piedmont Cancer Institute, presented the data in an oral presentation (OA08.04) at ISLAC 2024 World Conference on Lung Cancer on September 9th 2024 in San Diego, CA. Concurrently, Dublin-3 study was published in the Lancet Respiratory Medicine (View Source(24)00178-4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Docetaxel remains the standard of care for patients with 2L/3L NSCLC without targetable alterations despite severe neutropenia (>40%) that greatly impair patients’ quality of life. Six recent phase 3 studies in patients with EGFR wild-type NSCLC who were previously treated with immune checkpoint inhibitors failed to show overall survival (OS) benefit compared with docetaxel (SAPPHIRE, LEAP-008, CONTACT01, EVOKE-01, CARMEN-LC03, and CANOPY-2). Two phase 3 studies (LUNAR and TROPION-Lung01) showed positive but mixed outcomes compared with docetaxel.

The DUBLIN-3 study was a multicenter, randomized, single-blind, placebo-controlled trial that enrolled patients from 58 medical centers internationally. For the intention-to-treat (ITT) population, 559 patients received either docetaxel plus plinabulin (n=278 [male 199, female 79]) or docetaxel plus placebo (n=281 [male 207, female 74]).

Key findings of Dublin-3 study are summarized below:

Favorable benefit/risk ratio: Significant improvement in OS (Hazard ratio or HR=0.82; same HR in the Western vs. Asian patients), PFS (HR=0.79) and ORR (nearly doubled). Durable anti-cancer benefits in doubling 24-months and 36-months OS rates. And 82% relative reduction in Grade 4 neutropenia in Cycle 1 Day 8 (p<0.0001).
Consistent OS benefit in 24-month follow up after the database lock: OS HR=0.81 in the ITT population, with better OS benefit in the non-squamous subset (OS HR=0.72, p=0.0078). For the non-squamous subset patients, median OS (mOS) in plinabulin/docetaxel arm was 11.4 months vs. 8.8 months in the docetaxel arm, with a mOS benefit of 2.6 months.
Improved OS benefit with more cycles of treatment (≥ 4, 6, 8, 10, or 12 cycles): for patients who used at least 4 cycles of treatment, OS HR=0.64, p=0.0027, with a mOS benefit of 4.8 months (plinabulin/docetaxel arm n=133; docetaxel arm n=127).
Plinabulin/docetaxel combination is well-tolerated: Treatment-emergent adverse-events occurred in 273/274 (99·6%) of patients in the plinabulin group and 276/278 (99·3%) in the control group. Higher incidences of Grade 3/4 gastrointestinal disorders (46 patients [16·8%] vs. 8 [2·9%]) and transient Grade 3 hypertension (50 patients [18·2%] vs. 8 [2·9%]) occurred in the plinabulin vs. control group.
"There is a poor prognosis for NSCLC patients without targetable alterations whose disease has progressed on platinum-based therapies. Unfortunately, multiple high-profile phase 3 studies failed to show overall survival benefit in this hard-to-treat population compared to standard of care docetaxel, a drug approved over 20 years ago. The data from DUBLIN-3 study demonstrates that the addition and proper sequencing of plinabulin to docetaxel has a favorable benefit/risk ratio compared with docetaxel alone and may have broad utility. This combination could be considered as a new treatment option for this population with high unmet medical needs", said Dr. Feinstein, a lead principal investigator of the DUBLIN-3 study at Piedmont Cancer Center, Atlanta.

Citation:

Han B., et al. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med. 2024 Sep 09: S2213-2600(24)00178-4.

About Plinabulin

Plinabulin is a novel first-in-class dendritic cell maturation agent with durable anti-cancer benefit observed across multiple clinical studies. As a reversible binder at a distinct tubulin pocket, plinabulin does not change tubulin dynamics or antagonize tubulin stabilizing agents, such as docetaxel, which contributes to its differentiated activity and tolerability compared to other tubulin binders. In addition, plinabulin significantly reduces chemotherapy induced neutropenia and could thereby increase docetaxel tolerability. Over 700 patients have been treated with plinabulin with good tolerability.

About Dublin-3 Study
DUBLIN-3 is a multicenter, single-blinded (patient) and randomized, phase 3 trial in 58 medical centers (US, China, and Australia). Only patients with EGFR wild-type NSCLC who had progressed after first-line platinum-based therapy were enrolled. Patients were randomized (1:1) to receive docetaxel (75 mg/m2) on Day 1 and either plinabulin (30 mg/m2) or placebo on Days 1 and 8 in 21-day cycles until progression, unacceptable toxicity, withdrawal, or death. Treated patients were included in the safety analysis and ITT population in the primary efficacy analyses (NCT02504489). The primary endpoint for the study was OS, and secondary endpoints were PFS, ORR, Duration of Response (DoR), Grade 4 neutropenia and Quality of Life.